ONWARD® Medical Publishes Prospectus for Listing of New Shares THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE (7)(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014) EINDHOVEN, the Netherlands, Oct. 24, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD) (the “Company” or “ONWARD Medical”), the medical technology company creating innovative spinal cord stimulation therapies to restore movement, function, and independence in people with spinal cord injury (SCI), announces today that it has published a prospectus for the admission to listing of 10...
Below are the highlights of the 3Q conference call. Ontex 3Q LFL top line growth of +1.7% was slightly lower than market consensus (whilst close to KBCS) and the company did also lower its FY24 LFL top line guidance (from 4-5% growth to 2-3%), citing some temporary elements on the ramp up of new US customers. 3Q adjusted EBITDA jumped 29% and was close to our and consensus forecasts, with FY24 adjusted EBITDA margin maintained at 12% which is the 9M24 level and also baked into our and consensus ...
Constellium: challenging conditions led to disappointing Q3 results and guidanceVerallia is already marketing new 2032 bonds, a precocity that raises questions.Eramet: Q3 2024 sales below expectations and acquisition of Tsingshan's lithium stake for USD 699mKering: EBIT guidance revised down again after very poor Q3Auchan to sell its Russian subsidiary (La Lettre)>...
Constellium : Challenging conditions led to disappointing Q3 results and guidanceKering : nouvelle révision en baisse de la guidance d’EBIT après un très mauvais T3Verallia commercialise déjà des nouvelles obligations 2032, une précocité qui interpelleEramet : CA T3 2024 inférieur aux attentes et acquisition de la part de Tsingshan dans le lithium pour 699 m USD Auchan s'apprêterait à vendre sa filiale en Russie (La Lettre)>...
>Q3 2024 14% below consensus on orders, but slightly above our expectations - BESI reported its Q3 2024 results which were globally above expectations but well below on orders (although slightly above our expectations). Orders were € 152m, up 19% y-o-y due to increased orders for hybrid bonding but down 18% q-o-q primarily due to fluctuations in hybrid bonding order patterns by customers (Intel ordered 26 systems in Q2). They were 14% below the consensus at € 176m but...
>Q3 2024 14% below consensus on orders, but slightly above our expectations - BESI reported its Q3 2024 results which were globally above expectations but well below on orders (although slightly above our expectations). Orders were € 152m, up 19% y-o-y due to increased orders for hybrid bonding but down 18% q-o-q primarily due to fluctuations in hybrid bonding order patterns by customers (Intel ordered 26 systems in Q2). They were 14% below the consensus at € 176m but...
>Back to organic growth, albeit at rather careful levels - Azelis’ end-markets are showing signs of a recovery in volumes, albeit at a still very prudent pace it seems. The company generated Q3 24 revenues of € 1,054m, c. +2% yoy and -2% vs ccs. Group organic growth in the quarter was positive (+2.8% yoy) for the first time in roughly two years, an indication that markets are slowly recovering, albeit from a relatively easy comp base. Operating EBITA for the quarter w...
>Slight miss on overall sales whereas Core Margins came in line with the market - Ontex Group reported a 2% miss on sales for Q3 which came at €536.2m, while being 2% lower than the median company compiled consensus (css) of €548.3m. On a like for like (lfl) basis, total sales were up 1% year-on-year (yoy). In Core markets (continued operations), Ontex realised a 2% miss on consensus (css: € 478.3m) and is 2.4% higher yoy than Q3 2023 (€ 456.9m) whereas like-for-like ...
Onward has completed an upsized € 50m capital increase, which included a € 22.5m ticket from Ottobock, a global player in the fields of prosthetics, orthotics and exoskeleton technology, as new cornerstone investor. The new shares were issued at € 5.00 p.s., representing a 12.6% discount vs. last closing price. Given KBCS' involvement in the transaction, we temporarily suspended coverage until settlement on October 28.
Ontex 3Q LFL top line growth of +1.7% was slightly lower than market consensus (whilst close to KBCS) and the company did also lower its FY24 LFL top line guidance (from 4-5% growth to 2-3%), citing some temporary elements on the ramp up of new US customers. 3Q adjusted EBITDA jumped 29% and was close to our and consensus forecasts, with FY24 adjusted EBITDA margin maintained at 12% which is the 9M24 level and also baked into our and consensus forecasts for FY24. With the recent agreement to div...
Acomo: Hot Chocolate. Azelis: 3Q24 not flawless, but organic growth is back. BE Semiconductor Industries: 3Q24 results, putting its money where its mouth is. Ebusco: Rigorous turnaround plan, but many liquidity related concerns; recommendation moves to Under Review. GBL: Looking to take vitamins. Kinepolis: Solid 3Q24 attendance, in line, confident in the movie outlook for 4Q24, 2025. Ontex: Guidance Stumble. Unilever: Momentum maintained. Vastned: End of the disposal program, wa...
Over the last couple of weeks, logistics and WDP in particular have been hammered by economic fears in Europe. We believe the market enters a post-COVID normalisation phase and that structural growth drivers will remain resilient. For years, WDP anticipated a tougher economic climate. It brought its LTV% down to 35% in anticipation of distressed asset sales. While speculative developers have retreated, WDP has not found large scale opportunities in Germany. In France, some portfolios are floatin...
ONWARD® Medical Successfully Raises EUR 50 Million in an Upsized Capital Increase with Cornerstone Investment from Ottobock SE & Co. KGaA THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE (7)(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014) Ottobock, a global leader in the fields of prosthetics, orthotics and exoskeleton technology, acquires c.10% of ONWARD Medical N.V.’s share capital and initiates strategic relationship Cash runway extended to two years or more Capital increase was upsized to EUR 50M on the basis of strong demand from high-quality long-o...
ONWARD® Medical lève avec succès 50 millions d’euros dans le cadre d’une levée de fonds majorée avec le soutien d’Ottobock SE & Co. KGaA Ottobock, un leader mondial dans le domaine des prothèses, des orthèses et des exosquelettes, acquiert environ 10% du capital d’ONWARD Medical N.V. concrétisant un partenariat stratégique La couverture des besoins en trésorerie est étendue à deux ans ou plus Le montant de la levée de fonds a été majoré à 50 millions d’euros en raison de la forte demande d’investisseurs « long-only » de qualité et d’investisseurs spécialisés dans le secteur ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.